Pluri Inc

For the period ended Mar 31, 2024. Filed May 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

PLUR$1.12-5.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Interim Condensed Consolidated Statements of Operations

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Nine months ended March 31		Three months ended March 31,
	2024	2023	2024	2023
Revenues	$230	$176	$71	$87
Operating expenses:
Research and development expenses	$(10,066)	$(13,412)	$(3,362)	$(4,333)
Less: participation by the National Institute of Allergy and Infectious Diseases (“NIAID”), the Israeli Innovation Authority (“IIA”), Horizon Europe and other parties	1,015	1,189	268	166
Research and development expenses, net	(9,051)	(12,223)	(3,094)	(4,167)
General and administrative expenses	(7,303)	(8,655)	(2,511)	(3,020)
Operating loss	(16,124)	(20,702)	(5,534)	(7,100)
Interest expenses	(648)	(623)	(218)	(217)
Other financial income (expenses), net	1,290	(956)	362	(441)
Total financial income (expenses), net	642	(1,579)	144	(658)
Net loss	$(15,482)	$(22,281)	$(5,390)	$(7,758)
Net loss attributed to non-controlling interest	$(323)	$(419)	$(97)	$(134)
Net loss attributed to shareholders	$(15,159)	$(21,862)	$(5,293)	$(7,624)
Loss per share:
Basic and diluted net loss per share	$(2.92)	$(5.04)	$(1.01)	$(1.52)
Weighted average number of shares used in computing basic and diluted net loss per share (**)	5,193,808	4,402,130	5,221,162	4,993,451

(**)	See note 1d regarding reverse stock split

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.